ATE422357T1 - Verwendung von allopurinol zur behandlung von bluthochdruck - Google Patents
Verwendung von allopurinol zur behandlung von bluthochdruckInfo
- Publication number
- ATE422357T1 ATE422357T1 AT01946722T AT01946722T ATE422357T1 AT E422357 T1 ATE422357 T1 AT E422357T1 AT 01946722 T AT01946722 T AT 01946722T AT 01946722 T AT01946722 T AT 01946722T AT E422357 T1 ATE422357 T1 AT E422357T1
- Authority
- AT
- Austria
- Prior art keywords
- allopurinol
- treat hypertension
- administering
- patient
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21482500P | 2000-06-28 | 2000-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE422357T1 true ATE422357T1 (de) | 2009-02-15 |
Family
ID=22800556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01946722T ATE422357T1 (de) | 2000-06-28 | 2001-06-28 | Verwendung von allopurinol zur behandlung von bluthochdruck |
Country Status (8)
Country | Link |
---|---|
US (3) | US7799794B2 (de) |
EP (1) | EP1317258B1 (de) |
JP (1) | JP2004517804A (de) |
AT (1) | ATE422357T1 (de) |
AU (1) | AU2001268734A1 (de) |
CA (1) | CA2413201A1 (de) |
DE (1) | DE60137635D1 (de) |
WO (1) | WO2002000210A2 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236488B2 (en) | 2003-11-14 | 2012-08-07 | Human Cell Systems, Inc. | Method of screening for therapeutic compounds for vascular disorders and hypertension based on URAT1 activity modulation |
PL1750862T3 (pl) | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
EP1778261A4 (de) * | 2004-07-21 | 2010-08-11 | Univ Florida | Zusammensetzungen und verfahren zur behandlung und diagnose von insulinresistenz |
US8841333B2 (en) | 2005-05-09 | 2014-09-23 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for treating nephrolithiasis |
JP2009501795A (ja) * | 2005-07-21 | 2009-01-22 | ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド | 高尿酸血に関連する健康状態の治療及び予防のための組成物及び方法 |
US20070167454A1 (en) * | 2005-08-03 | 2007-07-19 | Christopher Lademacher | Methods for treating hypertension |
US20070208041A1 (en) * | 2005-10-13 | 2007-09-06 | Stamler Jonathan S | Compositions for the treatment and prevention of heart disease and methods of using same |
WO2008002911A2 (en) * | 2006-06-26 | 2008-01-03 | University Of Florida Research Foundation, Inc. | Urate metabolites as diagnostic markers for cardiovascular and renal disease |
EP2101761A4 (de) * | 2006-11-13 | 2010-01-27 | Takeda Pharmaceuticals North A | Verfahren zur konservierung der nierenfunktion mit xanthin-oxidoreductase-hemmern |
US20090124623A1 (en) * | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
US20090042887A1 (en) * | 2007-01-19 | 2009-02-12 | Tap Pharmaceutical Products, Inc. | Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents |
KR20100053609A (ko) * | 2007-09-05 | 2010-05-20 | 사노피-아벤티스 | 허혈성 또는 재관류 사건에 의해 유발된 심장의 장애 또는 간접적 후유증을 치료 또는 예방하기 위한 요산 산화효소의 용도 |
CN102256488A (zh) * | 2008-10-19 | 2011-11-23 | 理查德·J·约翰逊 | 伴随代谢失衡慢性肾病的治疗组合物和治疗方法 |
US20100311756A1 (en) * | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
JP5405140B2 (ja) * | 2009-02-16 | 2014-02-05 | 花王株式会社 | アディポネクチン増加剤 |
CA2764597A1 (en) * | 2009-06-26 | 2010-12-29 | Teijin Pharma Limited | Therapeutic drug for hypertension or high-normal blood pressure |
JP2011098896A (ja) * | 2009-11-04 | 2011-05-19 | Kirin Holdings Co Ltd | 尿酸値低下用組成物 |
WO2012033720A1 (en) * | 2010-09-08 | 2012-03-15 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
JP5978216B2 (ja) | 2010-09-10 | 2016-08-24 | タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド | テオフィリンとフェブキソスタットの併用療法のための方法 |
US10806711B2 (en) | 2011-08-12 | 2020-10-20 | University Of Cincinnati | Method of treating acute decompensated heart failure with probenecid |
EP2968238A1 (de) | 2013-03-13 | 2016-01-20 | University of Cincinnati | Behandlung von diastolischer kardialer dysfunktion mit einem trpv2-rezeptoragonisten |
WO2014140868A2 (en) | 2013-03-15 | 2014-09-18 | Allen Davidoff | Xanthine oxidase inhibitor formulations |
CA2952069C (en) | 2014-06-16 | 2022-06-14 | University Of Rochester | Small molecule anti-scarring agents |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7017486A (de) * | 1969-12-15 | 1971-06-17 | ||
US4058614A (en) * | 1973-12-04 | 1977-11-15 | Merck & Co., Inc. | Substituted imidazole compounds and therapeutic compositions therewith |
SE412587B (sv) | 1973-12-04 | 1980-03-10 | Merck & Co Inc | Forfarande for framstellning av substituerade imidazoler |
US4296122A (en) | 1975-07-09 | 1981-10-20 | Merck & Co., Inc. | 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids |
DE2707270A1 (de) * | 1977-02-19 | 1978-08-24 | Hoechst Ag | Pyrazolo-diazepine und verfahren zu ihrer herstellung |
DE2707269A1 (de) | 1977-02-19 | 1978-08-24 | Hoechst Ag | Heterocyclische stickstoffverbindungen und verfahren zu ihrer herstellung |
DE2727802A1 (de) | 1977-06-21 | 1979-04-19 | Hoechst Ag | Sulfamoyl-arylketone und verfahren zu ihrer herstellung |
US4510322A (en) * | 1981-07-13 | 1985-04-09 | Merck & Co., Inc. | Indacrinone having enhanced uricosuric |
DE3232922A1 (de) | 1982-09-04 | 1984-03-08 | Hoechst Ag, 6230 Frankfurt | Sulfamoylbenzophenon-derivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen |
DE3235565A1 (de) * | 1982-09-25 | 1984-03-29 | Boehringer Ingelheim KG, 6507 Ingelheim | Piperidinderivate, ihre herstellung und verwendung |
US4883821A (en) | 1988-04-13 | 1989-11-28 | Eisai Co., Ltd. | Agent for treating hyperuricemia |
JPH0366669A (ja) | 1989-08-03 | 1991-03-22 | Shionogi & Co Ltd | 複素環式化合物 |
US5260322A (en) | 1990-10-08 | 1993-11-09 | Merck & Co., Inc. | Angiotension II antagonists in the treatment of hyperuricemia |
DK0603301T3 (da) | 1991-09-09 | 1998-09-14 | Warner Lambert Co | Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist |
DK9200258U4 (da) * | 1992-03-11 | 1993-07-23 | Merck & Co Inc | Farmaceutisk præparat indeholdende enalapril til brug mod hypertension |
CA2186606A1 (en) * | 1994-03-29 | 1995-10-05 | Edward B. Nelson | Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles |
CA2183834C (en) * | 1995-08-22 | 2003-09-09 | Hiroshi Maeda | Antihypertensive agents containing pyrazolopyrimidine derivatives |
US6087386A (en) * | 1996-06-24 | 2000-07-11 | Merck & Co., Inc. | Composition of enalapril and losartan |
AU1520699A (en) * | 1997-11-07 | 1999-05-31 | Johns Hopkins University, The | Methods for treatment of disorders of cardiac contractility |
RU2278680C2 (ru) | 1998-08-06 | 2006-06-27 | Маунтэн Вью Фармасьютикэлз, Инк. | Способ изолирования тетрамерной формы уриказы и уриказа, полученная данным способом |
-
2001
- 2001-06-28 AT AT01946722T patent/ATE422357T1/de not_active IP Right Cessation
- 2001-06-28 CA CA002413201A patent/CA2413201A1/en not_active Abandoned
- 2001-06-28 AU AU2001268734A patent/AU2001268734A1/en not_active Abandoned
- 2001-06-28 JP JP2002504992A patent/JP2004517804A/ja active Pending
- 2001-06-28 DE DE60137635T patent/DE60137635D1/de not_active Expired - Lifetime
- 2001-06-28 US US09/892,505 patent/US7799794B2/en not_active Expired - Fee Related
- 2001-06-28 EP EP01946722A patent/EP1317258B1/de not_active Expired - Lifetime
- 2001-06-28 WO PCT/US2001/020457 patent/WO2002000210A2/en active Application Filing
-
2007
- 2007-04-04 US US11/696,330 patent/US20070232551A1/en not_active Abandoned
-
2009
- 2009-01-27 US US12/360,501 patent/US20090130078A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002000210A2 (en) | 2002-01-03 |
US20020019360A1 (en) | 2002-02-14 |
JP2004517804A (ja) | 2004-06-17 |
US20090130078A1 (en) | 2009-05-21 |
DE60137635D1 (de) | 2009-03-26 |
EP1317258A2 (de) | 2003-06-11 |
WO2002000210A3 (en) | 2002-10-24 |
CA2413201A1 (en) | 2002-01-03 |
EP1317258B1 (de) | 2009-02-11 |
US7799794B2 (en) | 2010-09-21 |
AU2001268734A1 (en) | 2002-01-08 |
US20070232551A1 (en) | 2007-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE422357T1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
CY1123084T1 (el) | Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι | |
ATE355852T1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
DE60113548D1 (de) | Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung | |
BRPI0006634B8 (pt) | composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
DE60128540D1 (de) | Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen | |
CY1107640T1 (el) | Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη | |
CY1109191T1 (el) | Μια νεα χρηση της δεφεριπρονης | |
ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
NO20071704L (no) | Prostaglandinderivater for behandling av gastrointestinal forstyrrelse | |
DE60330888D1 (de) | Verwendung von drospirenon zur behandlung von hypertension | |
ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
DE69932922D1 (de) | Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen | |
DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
ATE297739T1 (de) | Endothelin-antagonisten zur behandlung von herzversagen | |
ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
ATE382354T1 (de) | Präoperative behandlung von postoperativen schmerzen | |
AU2003283227A8 (en) | Method and means for the treatment of vascular and cardiac diseases | |
ATE315387T1 (de) | Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz | |
DE60128084D1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl | |
SE0100873D0 (sv) | Method of treatment | |
ATE268170T1 (de) | Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz | |
ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
DE69928814D1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |